Important Notice for Regeneron Pharmaceuticals, Inc. Shareholders
January 27, 2025 – The Gross Law Firm announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (REGN) who purchased shares during the period from October 20, 2020, to December 21, 2022. The lawsuit alleges that Regeneron Pharmaceuticals, Inc. and certain of its top executives violated the Securities Exchange Act of 1934.
Class Period and Eligibility
The class period is from October 20, 2020, to December 21, 2022. If you purchased Regeneron Pharmaceuticals, Inc. shares during this period, you may be a class member and eligible to participate in the action.
Allegations against Regeneron Pharmaceuticals, Inc.
The complaint alleges that Regeneron Pharmaceuticals, Inc. and its executives made false and misleading statements regarding the company’s business, operations, and prospects. Specifically, the complaint alleges that Regeneron Pharmaceuticals, Inc. failed to disclose material information regarding the safety and efficacy of its drug, Eylea, and its impact on the company’s financial results. As a result of these alleged false statements, Regeneron Pharmaceuticals, Inc. shares traded at artificially inflated prices during the class period.
Possible Lead Plaintiff Appointment
The Gross Law Firm encourages shareholders to contact the firm if they wish to discuss their role and potential leadership in this litigation. Shareholders who wish to serve as lead plaintiff are required to move the Court no later than March 28, 2025. The lead plaintiff will represent the interests of the class in this action and, if approved by the Court, will be entitled to certain fees and expenses.
Impact on Individual Investors
If the allegations in the complaint are proven true, Regeneron Pharmaceuticals, Inc. shareholders who purchased shares during the class period may be able to recover their losses. The extent of their potential recovery will depend on the size of their investment and the outcome of the litigation. It is important for investors to stay informed about the progress of this case as it unfolds.
Impact on the World
The outcome of this class action lawsuit could have significant implications for the biotech industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of drug safety and efficacy data, as well as increased transparency around financial reporting. Additionally, it could potentially lead to increased investor protection and stronger corporate governance practices.
Conclusion
If you purchased Regeneron Pharmaceuticals, Inc. shares during the class period listed in this notice, you may be a class member in a securities class action lawsuit. The Gross Law Firm encourages you to contact the firm to discuss your potential role and eligibility for compensation. The outcome of this case could have significant implications for individual investors and the biotech industry as a whole. Stay informed and stay involved.
- Regeneron Pharmaceuticals, Inc. shareholders who purchased shares during the class period may be eligible to participate in a securities class action lawsuit.
- The lawsuit alleges that Regeneron Pharmaceuticals, Inc. and certain executives violated securities laws by making false and misleading statements regarding the company’s business, operations, and prospects.
- Shareholders who wish to serve as lead plaintiff in the litigation must move the Court by March 28, 2025.
- The outcome of this case could have significant implications for individual investors and the biotech industry as a whole.
